Documento di consenso intersocietario ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: La terapia antiaggregante a lungo termine nel paziente con malattia coronarica

Translated title of the contribution: ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease

Michele Massimo Gulizia, Furio Colivicchi, Maurizio Giuseppe Abrignani, Marco Ambrosetti, Nadia Aspromonte, Gabriella Barile, Roberto Caporale, Giancarlo Casolo, Emilia Chiuini, Andrea Di Lenarda, Pompilio Faggiano, Domenico Gabrielli, Giovanna Geraci, Alessio Gaetano La Manna, Aldo Pietro Maggioni, Alfredo Marchese, Ferdinando Maria Massari, Gian Francesco Mureddu, Giuseppe Musumeci, Federico NardiAntonio Vittorio Panno, Roberto Franco Enrico Pedretti, Massimo Piredda, Enrico Pusineri, Carmine Riccio, Roberta Rossini, Fortunato Scotto Di Uccio, Stefano Urbinati, Ferdinando Varbella, Giovanni Battista Zito, Leonardo De Luca

Research output: Contribution to journalArticle

Abstract

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS) and/or receiving coronary stents. Long-term (>1 year) DAPT may further reduce the risk of stent thrombosis after percutaneous coronary intervention (PCI) and may decrease the occurrence of non-stent-related ischemic events in patients with ACS. Nevertheless, compared with aspirin alone, extended use of aspirin plus a P2Y12 receptor inhibitor may increase the risk of bleeding events that have been strongly linked to adverse outcomes including recurrent ischemia, repeat hospitalization, and death. Over the last years, multiple randomized clinical trials have been published comparing duration of DAPT after PCI and in ACS patients investigating either a shorter or prolonged DAPT regimen.Although current European Society of Cardiology guidelines provide backup to individualize treatment, it seems difficult to identify the ideal patient profile who could safely reduce or prolong DAPT duration in daily clinical practice. The aim of this consensus document is to review the contemporary literature on optimal DAPT duration and to guide clinicians in tailoring antiplatelet strategies in patients undergoing PCI or presenting with ACS.

Original languageItalian
Pages (from-to)263-331
Number of pages69
JournalGiornale italiano di cardiologia (2006)
Volume19
Issue number5
DOIs
Publication statusPublished - May 2018

Fingerprint

Coronary Artery Disease
Acute Coronary Syndrome
Percutaneous Coronary Intervention
Aspirin
Therapeutics
Stents
Hospitalization
Thrombosis
Ischemia
Randomized Controlled Trials
Guidelines
Hemorrhage

Cite this

Documento di consenso intersocietario ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA : La terapia antiaggregante a lungo termine nel paziente con malattia coronarica. / Gulizia, Michele Massimo; Colivicchi, Furio; Abrignani, Maurizio Giuseppe; Ambrosetti, Marco; Aspromonte, Nadia; Barile, Gabriella; Caporale, Roberto; Casolo, Giancarlo; Chiuini, Emilia; Di Lenarda, Andrea; Faggiano, Pompilio; Gabrielli, Domenico; Geraci, Giovanna; La Manna, Alessio Gaetano; Maggioni, Aldo Pietro; Marchese, Alfredo; Massari, Ferdinando Maria; Mureddu, Gian Francesco; Musumeci, Giuseppe; Nardi, Federico; Panno, Antonio Vittorio; Pedretti, Roberto Franco Enrico; Piredda, Massimo; Pusineri, Enrico; Riccio, Carmine; Rossini, Roberta; Scotto Di Uccio, Fortunato; Urbinati, Stefano; Varbella, Ferdinando; Zito, Giovanni Battista; De Luca, Leonardo.

In: Giornale italiano di cardiologia (2006), Vol. 19, No. 5, 05.2018, p. 263-331.

Research output: Contribution to journalArticle

Gulizia, MM, Colivicchi, F, Abrignani, MG, Ambrosetti, M, Aspromonte, N, Barile, G, Caporale, R, Casolo, G, Chiuini, E, Di Lenarda, A, Faggiano, P, Gabrielli, D, Geraci, G, La Manna, AG, Maggioni, AP, Marchese, A, Massari, FM, Mureddu, GF, Musumeci, G, Nardi, F, Panno, AV, Pedretti, RFE, Piredda, M, Pusineri, E, Riccio, C, Rossini, R, Scotto Di Uccio, F, Urbinati, S, Varbella, F, Zito, GB & De Luca, L 2018, 'Documento di consenso intersocietario ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: La terapia antiaggregante a lungo termine nel paziente con malattia coronarica', Giornale italiano di cardiologia (2006), vol. 19, no. 5, pp. 263-331. https://doi.org/10.1714/2907.29280
Gulizia, Michele Massimo ; Colivicchi, Furio ; Abrignani, Maurizio Giuseppe ; Ambrosetti, Marco ; Aspromonte, Nadia ; Barile, Gabriella ; Caporale, Roberto ; Casolo, Giancarlo ; Chiuini, Emilia ; Di Lenarda, Andrea ; Faggiano, Pompilio ; Gabrielli, Domenico ; Geraci, Giovanna ; La Manna, Alessio Gaetano ; Maggioni, Aldo Pietro ; Marchese, Alfredo ; Massari, Ferdinando Maria ; Mureddu, Gian Francesco ; Musumeci, Giuseppe ; Nardi, Federico ; Panno, Antonio Vittorio ; Pedretti, Roberto Franco Enrico ; Piredda, Massimo ; Pusineri, Enrico ; Riccio, Carmine ; Rossini, Roberta ; Scotto Di Uccio, Fortunato ; Urbinati, Stefano ; Varbella, Ferdinando ; Zito, Giovanni Battista ; De Luca, Leonardo. / Documento di consenso intersocietario ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA : La terapia antiaggregante a lungo termine nel paziente con malattia coronarica. In: Giornale italiano di cardiologia (2006). 2018 ; Vol. 19, No. 5. pp. 263-331.
@article{a68f3ab0f2464371a5969471401c529a,
title = "Documento di consenso intersocietario ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: La terapia antiaggregante a lungo termine nel paziente con malattia coronarica",
abstract = "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS) and/or receiving coronary stents. Long-term (>1 year) DAPT may further reduce the risk of stent thrombosis after percutaneous coronary intervention (PCI) and may decrease the occurrence of non-stent-related ischemic events in patients with ACS. Nevertheless, compared with aspirin alone, extended use of aspirin plus a P2Y12 receptor inhibitor may increase the risk of bleeding events that have been strongly linked to adverse outcomes including recurrent ischemia, repeat hospitalization, and death. Over the last years, multiple randomized clinical trials have been published comparing duration of DAPT after PCI and in ACS patients investigating either a shorter or prolonged DAPT regimen.Although current European Society of Cardiology guidelines provide backup to individualize treatment, it seems difficult to identify the ideal patient profile who could safely reduce or prolong DAPT duration in daily clinical practice. The aim of this consensus document is to review the contemporary literature on optimal DAPT duration and to guide clinicians in tailoring antiplatelet strategies in patients undergoing PCI or presenting with ACS.",
author = "Gulizia, {Michele Massimo} and Furio Colivicchi and Abrignani, {Maurizio Giuseppe} and Marco Ambrosetti and Nadia Aspromonte and Gabriella Barile and Roberto Caporale and Giancarlo Casolo and Emilia Chiuini and {Di Lenarda}, Andrea and Pompilio Faggiano and Domenico Gabrielli and Giovanna Geraci and {La Manna}, {Alessio Gaetano} and Maggioni, {Aldo Pietro} and Alfredo Marchese and Massari, {Ferdinando Maria} and Mureddu, {Gian Francesco} and Giuseppe Musumeci and Federico Nardi and Panno, {Antonio Vittorio} and Pedretti, {Roberto Franco Enrico} and Massimo Piredda and Enrico Pusineri and Carmine Riccio and Roberta Rossini and {Scotto Di Uccio}, Fortunato and Stefano Urbinati and Ferdinando Varbella and Zito, {Giovanni Battista} and {De Luca}, Leonardo",
year = "2018",
month = "5",
doi = "10.1714/2907.29280",
language = "Italian",
volume = "19",
pages = "263--331",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "5",

}

TY - JOUR

T1 - Documento di consenso intersocietario ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA

T2 - La terapia antiaggregante a lungo termine nel paziente con malattia coronarica

AU - Gulizia, Michele Massimo

AU - Colivicchi, Furio

AU - Abrignani, Maurizio Giuseppe

AU - Ambrosetti, Marco

AU - Aspromonte, Nadia

AU - Barile, Gabriella

AU - Caporale, Roberto

AU - Casolo, Giancarlo

AU - Chiuini, Emilia

AU - Di Lenarda, Andrea

AU - Faggiano, Pompilio

AU - Gabrielli, Domenico

AU - Geraci, Giovanna

AU - La Manna, Alessio Gaetano

AU - Maggioni, Aldo Pietro

AU - Marchese, Alfredo

AU - Massari, Ferdinando Maria

AU - Mureddu, Gian Francesco

AU - Musumeci, Giuseppe

AU - Nardi, Federico

AU - Panno, Antonio Vittorio

AU - Pedretti, Roberto Franco Enrico

AU - Piredda, Massimo

AU - Pusineri, Enrico

AU - Riccio, Carmine

AU - Rossini, Roberta

AU - Scotto Di Uccio, Fortunato

AU - Urbinati, Stefano

AU - Varbella, Ferdinando

AU - Zito, Giovanni Battista

AU - De Luca, Leonardo

PY - 2018/5

Y1 - 2018/5

N2 - Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS) and/or receiving coronary stents. Long-term (>1 year) DAPT may further reduce the risk of stent thrombosis after percutaneous coronary intervention (PCI) and may decrease the occurrence of non-stent-related ischemic events in patients with ACS. Nevertheless, compared with aspirin alone, extended use of aspirin plus a P2Y12 receptor inhibitor may increase the risk of bleeding events that have been strongly linked to adverse outcomes including recurrent ischemia, repeat hospitalization, and death. Over the last years, multiple randomized clinical trials have been published comparing duration of DAPT after PCI and in ACS patients investigating either a shorter or prolonged DAPT regimen.Although current European Society of Cardiology guidelines provide backup to individualize treatment, it seems difficult to identify the ideal patient profile who could safely reduce or prolong DAPT duration in daily clinical practice. The aim of this consensus document is to review the contemporary literature on optimal DAPT duration and to guide clinicians in tailoring antiplatelet strategies in patients undergoing PCI or presenting with ACS.

AB - Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS) and/or receiving coronary stents. Long-term (>1 year) DAPT may further reduce the risk of stent thrombosis after percutaneous coronary intervention (PCI) and may decrease the occurrence of non-stent-related ischemic events in patients with ACS. Nevertheless, compared with aspirin alone, extended use of aspirin plus a P2Y12 receptor inhibitor may increase the risk of bleeding events that have been strongly linked to adverse outcomes including recurrent ischemia, repeat hospitalization, and death. Over the last years, multiple randomized clinical trials have been published comparing duration of DAPT after PCI and in ACS patients investigating either a shorter or prolonged DAPT regimen.Although current European Society of Cardiology guidelines provide backup to individualize treatment, it seems difficult to identify the ideal patient profile who could safely reduce or prolong DAPT duration in daily clinical practice. The aim of this consensus document is to review the contemporary literature on optimal DAPT duration and to guide clinicians in tailoring antiplatelet strategies in patients undergoing PCI or presenting with ACS.

U2 - 10.1714/2907.29280

DO - 10.1714/2907.29280

M3 - Articolo

C2 - 29853716

VL - 19

SP - 263

EP - 331

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 5

ER -